Multiple Sclerosis (MS)

Table of Contents

  1. Disorder

  2. Epidemiology

  3. Pathophysiology

  4. Risk Factors & Associations

  5. Signs & Symptoms

  6. Diagnostic Criteria

  7. Diagnostic Workup

  8. Disease Modifying Therapy (DMT)

  9. Non-DMT Treatment

  10. Followup

  11. Scales

  12. Prognosis

  13. References

Pathophysiology

Risk factors & Associations

Signs & Symptoms

Diagnostic Criteria

Diagnostic Workup

Disease Modifying Therapy (DMT)

Disorder

Epidemiology

Infusions

  • Natalizumab (Tysabri)

  • Ocrelizumab (Ocrevus)

  • Ofatumumab

  • Alemtuzumab

  • Ublituximab-xiiy (Briumvi)

  • Cladribine (Mavenclad)

  • Mitoxantrone (Novantrone)

Non-DMT Therapies

Followup

Scales

Prognosis

References

Oral Medications

  • Teriflunomide (Aubagio)

  • Monomethyl fumarate (Bafiertam)

  • Dimethyl fumarate (Tecfidera)

  • Diroximel fumarate (Vumerity)

  • Fingolimod (Gilenya)

  • Siponimod (Mayzent)

  • Ozanimod (Zeposia)

  • Ponesimod (Ponvory)

Self -injected Medications

  • Interferon beta-1a (Avonex, Rebif)

  • Interferon beta-1b (Betaseron)

  • Peginterferon beta-1a (Plegridy)

  • Glatiramer acetate (Copaxone)

  • Ofatumumab (Kesimpta)